121 results about "Airway disease" patented technology

The present invention relates to pharmaceutical compositions for inhalation comprising glycopyrrolate, a beta2-agonist, and optionally an inhaled corticosteroid; 103501776to a process for preparing such compositions and to the use of such compositions for the prevention and / or treatment of respiratory, inflammatory or obstructive airway disease.

A removable intraoral apparatus for improving airway patency is described. Wearing the apparatus alters the position, configuration and freedom of movement of the tongue, the muscles of mastication, as well as the pharyngeal and facial muscles. The apparatus is useful for correcting snoring and / or obstructive sleep apnea due to intermittent closures or partial obstructions occurring in the oropharynx during sleep. The apparatus of the invention can improve various types of airway disorders and improve oral functions by changing the position, configuration and freedom of movement of selected portions of the tongue and mouth, reducing the resistance to air flow in the mouth and pharynx, re-orienting and reprogramming the muscles of the mouth and tongue, and maintaining a proper oral systemic balance.

The present invention is directed to a method of using compounds of Formula (I) to inhibit Cathepsin B. Specifically the compounds of the present invention are useful as therapeutic agents for the treatment of tumor invasion, metastasis, Alzheimer's Disease, arthritis, inflammatory diseases such as chronic and acute pancreatitis, inflammatory airway disease, and bone and joint disorders, including osteoporosis, osteoarthritis, rheumatoid arthritis, psoriasis, and other autoimmune disorders, liver fibrosis, including liver fibrosis associated with HCV, all types of steatosis (including non-alcoholic steatohepatitis) and alcohol-associated steatohepatitis, non-alcoholic fatty liver disease, forms of pulmonary fibrosis including idiopathic pulmonary fibrosis, pathological diagnosis of interstitial pneumonia following lung biopsy, renal fibrosis, cardiac fibrosis, retinal angiogenesis and fibrosis / gliosis in the eye, schleroderma, and systemic sclerosis. The compounds of Formula (I) are also useful for treating subjects with both HCV and fibrosis in a mammal, particularly liver fibrosis, and subjects affirmatively diagnosed or at risk for both HCV and liver fibrosis.